MicuRx Pharmaceuticals has received a US patent from the USPTO covering the composition of its clinical candidate, MRX-I. The antibacterial oxazolidinone targets infections due to multi-drug resistant Gram-positive pathogens. MicuRx ...
Tags: MicuRx Pharmaceuticals, MRX-I